Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 6Completed 6Active not recruiting 4Unknown 2Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Deafness, Autosomal Recessive 39 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × tepotinib × Clear all
NCT04739358 2023-10-18

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Criterium, Inc.

Phase 1/2 Terminated
2 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04515394 2022-12-22

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

EMD Serono

Phase 2 Terminated
3 enrolled 6 charts
Gastrointestinal

Deafness, Autosomal Recessive 39, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡